Crossmark Global Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

Crossmark Global Holdings’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,119	Closed	-$100K	–	1435
2021 Q2	$100K	Hold	10,119	–	–	﹤0.01%	1410
2021 Q1	$117K	Sell	10,119 -713	-7%	-$8.18K	﹤0.01%	1404
2020 Q4	$105K	Sell	10,832 -2,415	-18%	-$23.1K	﹤0.01%	1366
2020 Q3	$119K	Sell	13,247 -400	-3%	-$4.23K	﹤0.01%	1291
2020 Q2	$168K	Hold	13,647	–	–	﹤0.01%	1266
2020 Q1	$123K	Sell	13,647 -3,126	-19%	-$32K	﹤0.01%	1146
2019 Q4	$164K	Hold	16,773	–	–	﹤0.01%	1354
2019 Q3	$115K	Sell	16,773 -201	-1%	-$1.54K	﹤0.01%	1320
2019 Q2	$157K	Sell	16,974 -712	-4%	-$8.59K	﹤0.01%	1338
2019 Q1	$277K	Hold	17,686	–	–	0.01%	1159
2018 Q4	$273K	Hold	17,686	–	–	0.01%	1133
2018 Q3	$381K	Hold	17,686	–	–	0.01%	1153
2018 Q2	$430K	Sell	17,686 -503	-3%	-$10.3K	0.01%	1047
2018 Q1	$311K	Sell	18,189 -600	-3%	-$11.7K	0.01%	1242
2017 Q4	$356K	Sell	18,789 -3,550	-16%	-$53.4K	0.01%	1254
2017 Q3	$393K	Buy	+22,339	New	+$503K	0.01%	1119
2016 Q3	$393K	Buy	+22,339	New	+$1.17M	0.01%	1119

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Crossmark Global Holdings's TEVA Position: Q3 2021 in Review

Crossmark Global Holdings sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 10,119 shares — an estimated $100K sold.

Crossmark Global Holdings first reported a position in TEVA in Q3 2016 and held it in 17 quarters. The position peaked at $430K in Q2 2018. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

Crossmark Global Holdings reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Crossmark Global Holdings sold 10,119 Teva Pharmaceuticals shares in Q3 2021, an estimated $100K.
Crossmark Global Holdings first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 17 quarters.
Crossmark Global Holdings's Teva Pharmaceuticals position peaked at $430K in Q2 2018.
429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on Crossmark Global Holdings's 13F filing for Q3 2021, filed 13 Oct 2021.